Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (low-grade)

Sponsor ID

20010138

Clinicaltrials.gov ID

NCT00044902

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Additional Study Details

Phase

Phase 2

Product

epratuzumab

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Protocol Summary

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Locations

No locations found.